BRCA1 Breast Cancer: Carol's Survivor Story

Patient Info: Carol Arnhart

Biomarkers: BRCA1 mutation

She had a complete pathologic response to breast chemotherapy and later reported no evidence of breast cancer.

MD AndersonRead more →

Stage III HER2-Positive Breast Cancer: Christine's Survivor Story

Patient Info: Christine Elliott, Female, Under 40 | Stage III

Biomarkers: Estrogen receptor-positive; HER2 and progesterone receptor status not reported

As of May 2023, Christine was about 3 years from diagnosis and in survivorship after chemotherapy, lumpectomy, and radiation. She reported lasting physical and emotional effects but did not state a formal NED status.

YouTube — The Patient StoryRead more →

Rare breast blood-vessel cancer (angiosarcoma) in a teenage girl

Patient Info: Anonymized, Female

Biomarkers: Testing for Li-Fraumeni syndrome and POT1 mutation was inconclusive; no inherited cancer predisposition was established

She remained in remission 3 years after diagnosis and continued annual MRI surveillance of the reconstructed and opposite breasts.

PubMed CentralRead more →

Stage III Breast Cancer: Diana's Patient Story

Patient Info: Diana, Female, 40s | Stage III

As of 2023, Diana was receiving treatment for Stage III breast cancer after quadrantectomy, chemotherapy, radiation therapy, hormone therapy, unilateral oncological mammoplasty, and lymph-node removal.

Our Cancer StoriesRead more →

Metastatic Breast Cancer Treatment Caused Severe Circulation Problems in Her Fingers and Toes

Patient Info: Anonymized, Female | Stage IV

Biomarkers: HER2-positive; ER-negative; PR-negative

The digital ischaemia improved after gemcitabine was stopped, without revascularisation, debridement or amputation, although a small necrotic fingertip area persisted at 3 months. Metastatic breast cancer treatment continued with further systemic lines after progression.

PubMed CentralRead more →

Stage IV PIK3CA Breast Cancer: Abigail's Patient Story

Patient Info: Abigail, Female, Under 40 | Stage IV

Biomarkers: Hormone-positive breast cancer with PIK3CA mutation and germline ATM mutation; later PD-L1 somatic change reported. HER2 not stated.

Metastatic Site: Bone, including femurs, spine, and humeri; later liver

As of October 2022, Abigail was living with Stage IV hormone-positive metastatic breast cancer after years of treatment, bone-dominant disease that later involved the liver, targeted therapies, genomic testing, and advocacy around clinical trials and patient research participation.

The Patient StoryRead more →

Stage IIIC Primary Ovarian Leiomyosarcoma Treated With Debulking Surgery and Chemotherapy

Patient Info: Anonymized, Female | Stage III

Biomarkers: SMA positive; caldesmon positive; Ki-67 15%–20%; p53 negative

She recovered from extensive cytoreductive surgery, reported resolution of her symptoms, and began planned adjuvant Adriamycin and ifosfamide.

PubMed CentralRead more →

Severe Esophageal Narrowing After Chemotherapy for Breast Cancer

Patient Info: Anonymized, female, 60s

The breast tumor shrank slightly and was considered stable before mastectomy. Her major subsequent problem was persistent treatment-related esophageal narrowing that required nutritional support and later a removable esophageal stent.

PubMed CentralRead more →

Stage III Breast Cancer: Diana's Survivor Story

Patient Info: Diana, Female, 40s | Stage III

Diana described herself as being in remission while continuing low-toxicity antineoplastic monotherapy. She remained in active follow-up and focused on rebuilding daily life.

Our Cancer StoriesRead more →

Metastatic Clear Cell Ovarian Cancer Complicated by Treatment-Related Sarcoidosis

Patient Info: Anonymized, Female, 60s | Stage Metastatic/Advanced

Metastatic Site: peritoneum

During a treatment holiday, biopsy and laboratory evaluation showed treatment-related sarcoidosis rather than ovarian-cancer spread in the enlarged lymph nodes. After prednisone, the sarcoidosis resolved and imaging showed no progression of the clear cell ovarian cancer; she remained clinically well 4 months later.

PubMed CentralRead more →

HER2-positive left breast cancer treated with trastuzumab and mastectomy

Patient Info: Anonymized, Female, 60s | Stage Metastatic/Advanced

Biomarkers: ER-negative; PR-negative; HER2/CerbB2 strongly positive; BRCA1/2 negative for known pathogenic variants; FANCA variant of uncertain significance.

She remained alive, asymptomatic, and disease-free while undergoing annual surveillance after treatment for the left HER2-positive breast cancer.

PubMed CentralRead more →

A durable response to trastuzumab in heavily pretreated metastatic breast cancer

Patient Info: Anonymized, Female, 60s | Stage IV

Biomarkers: Initial tumor ER-positive and PR-positive. Metastatic liver biopsy ER-negative and PR-negative with HER2 IHC 1+ and nonamplified. Later biopsy ER and PR weakly positive at 5%–10%, HER2 IHC 1+ and nonamplified, and ERBB3 p. with evidence of HER2/HER3 pathway activation.

Metastatic Site: lungs; hilar and mediastinal lymph nodes; liver; bone

She had ongoing benefit for more than 10 months on trastuzumab and capecitabine, with improved symptoms, lower tumor markers, and a confirmed partial response.

PubMed CentralRead more →

Stage IV Breast Cancer: Harper's Patient Story

Patient Info: Harper, Female, 50s | Stage IV

Harper was living with Stage IV breast cancer after self-funded private treatment that included mastectomy, lymphadenectomy, chemotherapy, and radiation therapy; she felt better than before diagnosis but still hoped for complete recovery.

Our Cancer StoriesRead more →

Cherie's Stage 2 Breast Cancer Story After a Second Opinion

Patient Info: Cherie, Female, 50s | Stage II

Cherie described herself as being in remission while continuing hormone therapy. She remained concerned about relapse and used travel and painting to manage anxiety.

Our Cancer StoriesRead more →

HER2-positive breast cancer diagnosed during pregnancy and later spread to bone and brain

Patient Info: Anonymized, Female, Under 40 | Stage IV

Biomarkers: Initial tumour: ER 0%, PR <1%, HER2 3+

Metastatic Site: bone (L3)|brain

After treatment and surveillance without new lesions, she developed a large symptomatic occipital brain metastasis 14 months after completing paclitaxel and radiation and died after rapid neurological deterioration.

PubMed CentralRead more →

Triple-Negative Breast Cancer Treated With Mastectomy and Chemotherapy

Patient Info: Anonymized, Female, 40s

Biomarkers: Triple-negative.

The later accessory-breast-tissue cancer was considered a separate new primary after a five-year interval, and she was currently without evidence of disease.

PubMed CentralRead more →

HER2-Positive Breast Cancer Linked to a Rare Immune-Related Neurological Syndrome

Patient Info: Anonymized, Female, 40s

Biomarkers: HER2-positive in both foci; one focus ER-negative/PR-positive with Ki-67 45%; second focus ER-negative/PR-negative with Ki-67 35%; anti-Yo antibodies positive in serum and CSF; tumour-susceptibility gene panel negative

At 1 year, she had completed trastuzumab, continued tamoxifen, and had no evidence of recurrent breast cancer; intensive rehabilitation improved her mobility, although balance and right-sided neurological deficits persisted.

PubMed CentralRead more →

Bilateral Triple-Negative Breast Cancer Followed by Blood Clots and a Spinal-Fluid Leak

Patient Info: Anonymized, Female, 50s

Biomarkers: Triple-negative

Two years after chemotherapy, a recurrent cerebrospinal-fluid leak was repaired endoscopically and had not recurred at 12 months.

PubMed CentralRead more →

Early breast cancer followed 19 years later by a radiation-related breast sarcoma

Patient Info: Anonymized, Female, 70+ | Stage I

Biomarkers: Strongly ER-positive; strongly PR-positive.

The stage IA breast carcinoma remained disease-free for 19 years; a later right-breast mass was a separate radiation-induced sarcoma rather than recurrent carcinoma.

PubMed CentralRead more →

Dramatic chemotherapy response in stage IIIB triple-negative breast cancer

Patient Info: Anonymized, Female, 40s | Stage III

Biomarkers: ER-negative; PR-negative; HER2-negative; BRCA1-negative; BRCA2-negative; germline FLCN c.1285delC associated with Birt-Hogg-Dubé syndrome; tumor TP53 p.T150fs.

Eighteen months after surgery, she had no recurrence following a dramatic chemotherapy response, bilateral mastectomy, chest-wall radiation, and adjuvant capecitabine.

PubMed CentralRead more →

Breast Cancer: Constance's Survivor Story

Patient Info: Constance Porter, Female

As of January 2020, Constance was cancer-free 3 years after breast cancer diagnosis, while living with permanent hair loss, joint pain from anastrozole, and occasional leg cramps.

MD AndersonRead more →

ER-negative left breast cancer treated with mastectomy and chemotherapy

Patient Info: Anonymized, Female, 70+

Biomarkers: ER-negative; HER2-negative.

Her later cancer care centered on a separate right-breast primary diagnosed in 2008 and its subsequent metastatic course.

PubMed CentralRead more →

Stage IIIA breast cancer treated alongside a synchronous colon cancer

Patient Info: Anonymized, Female, 50s | Stage III

Two years after surgery, she remained well with no CT evidence of metastasis or recurrence while continuing endocrine therapy and six-monthly follow-up.

PubMed CentralRead more →

Breast Cancer Survivor Story: Chemo, Double Mastectomy, Radiation, Reconstruction

Patient Info: Margaret, Female | Stage II

Biomarkers: Oncotype DX score reported around 16-18; genetic testing negative; specific inherited gene not named

As of June 2019, Margaret was in remission after Stage II IDC treated with double mastectomy, AC/Taxol chemotherapy, radiation, and reconstruction.

The Patient StoryRead more →